Live Attenuated Varicella Vaccine Achieves 50% Seroconversion in Pediatric TNF-α Inhibitor Patients
Background
Patients receiving tumor necrosis factor-alpha (TNF-α) inhibitors for conditions like juvenile idiopathic arthritis or inflammatory bowel disease often have compromised immune systems, making live attenuated vaccines generally contraindicated. However, these vaccines are crucial for preventing serious infections. This study addresses the critical gap in understanding the immunogenicity and safety of the live attenuated varicella vaccine in this vulnerable population, where current guidelines often restrict vaccination.
Study Design
This single-center, prospective clinical trial enrolled 10 pediatric patients receiving TNF-α inhibitors. Eligibility required varicella-specific immunoglobulin G (IgG) levels <4.0 and meeting predefined cellular and humoral immunity criteria. Participants received a single dose of the live attenuated varicella vaccine. Varicella-specific IgG levels were measured before and after vaccination to assess immunogenicity. Patients were monitored for adverse events for up to 6 months post-vaccination.
Results
A single dose of the live attenuated varicella vaccine induced seroconversion (IgG level ≥4.0) in 50% (5 out of 10) of pediatric patients receiving TNF-α inhibitors.
Key Findings
- Live attenuated varicella vaccine achieved 50% seroconversion after a single dose in pediatric patients on TNF-α inhibitors.
- An additional 1 patient seroconverted after a booster dose, bringing total seroconversion to 60%.
- No vaccine-related adverse events were observed in the 10 patients over 6 months.
- The vaccine may be acceptable for use in patients receiving TNF-α inhibitors, pending larger studies.
Why It Matters
This pilot study provides initial, albeit limited, evidence that the live attenuated varicella vaccine may be acceptably safe and immunogenic in pediatric patients on TNF-α inhibitors, challenging the general contraindication. This finding suggests that clinicians may consider varicella vaccination in carefully selected patients under TNF-α inhibitor therapy, potentially reducing the risk of severe varicella infection. While not a definitive protocol, it opens the door for larger studies to establish clear guidelines, potentially altering current vaccination strategies for this vulnerable population.
varicella vaccine
tnf-alpha-inhibitors
immunogenicity
pediatric
autoimmune disease
live vaccine